Summary
InProTher (IPT) is developing a unique immunotherapy – BreakImmune – that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines. The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types.
Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors.
Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190120397 |
| Start date: | 01-07-2022 |
| End date: | 31-10-2025 |
| Total budget - Public funding: | 12 179 813,25 Euro - 2 500 000,00 Euro |
Cordis data
Original description
InProTher (IPT) is developing a unique immunotherapy – BreakImmune – that effectively targets endogenous retroviruses (HERVs) to treat cancer. HERVs are not expressed in normal tissues, but are expressed in several major cancers, such as breast (88%), prostate (90%), ovarian (90%), and pancreatic (80%). Thus, HERVs can be a potential target for the immune system to destroy tumor cells. IPT technology relies on the engineering of HERVK antigens to be used as effective cancer vaccines. The administration of BreakImmune, the mutated HERVK in Ad19/MVA viral vectors, induces both strong antibody and T-cell immune responses able to destroy cancer cells in multiple cancer types.Our first product is IPT001, a first in class vaccine against solid cancers in combination with checkpoint inhibitors.
Status
SIGNEDCall topic
HORIZON-EIC-2021-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
